{"id":2282,"date":"2023-09-28T19:23:17","date_gmt":"2023-09-28T19:23:17","guid":{"rendered":"https:\/\/sagemedic.com\/staging\/?post_type=awsm_job_openings&p=2282"},"modified":"2023-10-13T01:25:19","modified_gmt":"2023-10-13T01:25:19","slug":"oncology-business-development-executive","status":"publish","type":"awsm_job_openings","link":"https:\/\/sagemedic.com\/staging\/jobs\/oncology-business-development-executive\/","title":{"rendered":"Oncology Business Development Executive"},"content":{"rendered":"\n

Oncology Business Development Executive<\/strong><\/h4>\n\n\n\n

SageMedic (SAGE) is dramatically changing the way how physicians can treat cancer patients and give hope to their families. Instead of hoping that a therapy will work for a specific patient and starting a new regimen if it does not work, SAGE makes it possible for physicians to know, in advance, whether a specific traditional and\/or targeted cytotoxic therapy will be effective for an individual patient\u2019s tumor.<\/p>\n\n\n\n

SAGE also provides a unique opportunity for pharma companies developing cancer therapies, by being able to predict a patient\u2019s tumor response to a targeted therapy much more accurately than traditional genomic approaches. Not only would this be useful for lead compound selection, and thereby significantly increase the chance to select a clinically effective compound. At a later stage, SAGE would also empower pharma companies to demonstrate effectiveness to regulators faster and with fewer patients, speeding time to market for promising life-saving therapies. This business development opportunity allows you to help SageMedic transform the way that
new cancer treatments are developed \u2013 and the way that existing cancer treatments are marketed, prescribed, and reimbursed. It allows you to show pharma customers how they can deliver personalized medicine in a way that we\u2019ve all dreamed of doing, but have never before had the tools to make it possible.<\/p>\n\n\n\n

Your roles would be to meet with strategic marketing directors, therapeutic area VPs, program leaders, and clinical research directors of those pharma companies to show them how SageMedic\u2019s cancer drug screening platform can increase drug development efficacy, lowering costs, accelerate time-to-market and dramatically improve FDA success. You\u2019ll show them how SageMedic equips caregivers to identify the most effective treatment for the millions
of cancer patients where genomic testing fails. If you\u2019re a leader with a proven track record bringing game-changing breakthroughs to potential customers and driving adoption, this is an opportunity to transform the industry and save patients and families the heartbreak, despair, and uncertainty that have been part and parcel of a cancer diagnosis.<\/p>\n\n\n\n

Roles and Responsibilities<\/strong><\/h4>\n\n\n\n

You will be reporting directly to the CEO and work as part of a cross-functional team to refine the go-to-market strategy, and pricing, and develop supporting materials to approach pharmaceutical companies. Goal is to build up a strong and solid channel partner strategy and to develop materials for channel partners to use when they present SAGE to their customers. And you\u2019ll test those materials in pilot meetings you arrange with prospective
pharma customers and channel partners.<\/p>\n\n\n\n

As the direct sales strategy, marketing materials, and channel partner strategy get solidified, SAGE will rely on you to\u2026<\/p>\n\n\n\n